Sobi grabs emapalumab, anticipates 2018 approval

Swedish Orphan Biovitrum AB (SSE:SOBI) received exclusive, worldwide rights from Novimmune S.A. (Plan-les-Ouates, Switzerland) to hematology candidate emapalumab (NI-0501).

Novimmune will receive SEK450 million ($50.8

Read the full 245 word article

User Sign In